Drugs / SYH2061
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07241910 | Dec 2025 → Nov 2026 expected | — | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG (SYH2061 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2025-10-24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYH2061 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG (SYH2061 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2025-10-24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYH2061 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH2061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07241910 ↗ |
| Route | Subcutaneous | “Subjects in experimental group will receive a single subcutaneous injection of SYH2061 on Day 1.” NCT07241910 ↗ |